Cellectar Biosciences CLRB 深 滬
等待開盤 12-13 09:30:00 美东时间
3.62
-0.160
-4.23%
華盛通- 最 高3.85
- 今 開3.70
- 成交量 5.04万股
- 最 低 3.60
- 昨 收 3.78
- 總市值 1155.50万
- 52周最高 20.595
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.71
- 委 比 -56.86%
- 總股本 319.20万
- 歷史最高 276000.00
- 量 比 1.15
- 振 幅 6.61%
- 歷史最低 3.60
- 每 手 1
- 風險率 2.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.53) by 44.2 percent. This is a 88.25 percent increase over losses of $(12.00) per share
11-13 20:03
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cellectar Biosciences announced financial results for Q3 2025 and updates on its pipeline, including plans to submit a Conditional Marketing Authorization application for iopofosine I 131 in Europe for refractory Waldenstrom's macroglobulinemia in 2026. The company also initiated a Phase 1b study for CLR 125 in triple-negative breast cancer (TNBC) and received rare pediatric drug designation for iopofosine I 131 in inoperable relapsed/refractory ...
11-13 12:20
Earnings Outlook For Cellectar Biosciences
Cellectar Biosciences (NASDAQ:CLRB) is set to give its latest quarterly earning...
11-13 01:03
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Cellectar Biosciences, Inc. will report its third-quarter 2025 financial results and provide a corporate update on November 13, 2025, at 8:30 a.m. ET. A conference call and webcast will be held, accessible via 1-800-717-1738 (Conference ID: 42734) or the provided webcast link. A replay will be available on the company’s Investor Relations website. Cellectar focuses on developing radiopharmaceuticals for cancer treatment using its Phospholipid Dru...
11-06 13:05
CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
CLRB stock has given up its prior gain. Cellectar Biosciences shares were tradi...
10-27 21:27
Cellectar Biosciences shares are trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
Cellectar Biosciences shares are trading higher after the company received Rare...
10-27 20:33
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
Cellectar Biosciences announced that the FDA granted Rare Pediatric Drug Designation to iopofosine I 131 for treating inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG). Interim data from the CLOVER-2 Phase 1b trial showed extended progression-free survival (PFS) and overall survival (OS), with patients experiencing disease control and reduced tumor volume. The drug demonstrated a favorable safety profile, with no severe off...
10-27 12:30
Cellectar Biosciences Presented Preclinical Data On CLR 121225, A Novel Actinium-Based Alpha-Emitter For Pancreatic Ductal Adenocarcinoma Which Has Completed IND-Enabling Studies And May Advance To A Phase 1 Trial
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief
10-14 20:37
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Cellectar Biosciences announced promising preclinical data for CLR 225, a novel actinium-based radio conjugate targeting pancreatic ductal adenocarcinoma (PDAC). Studies showed significant tumor growth inhibition and potential survival benefits across three pancreatic cancer models. CLR 225 demonstrated safe biodistribution and linear pharmacokinetics, supporting its advancement to Phase 1 trials. The drug's ability to penetrate the dense extrace...
10-14 12:30
